Document is current
Any future updates will be listed below
-
Authors
Takamizawa, Shigemasa
Katsuya, Yuki
Chen, Yi-Ning
Mizuno, Takaaki
Koyama, Takafumi
Sudo, Kazuki
Yoshida, Tatsuya
Kondo, Shunsuke
Iwasa, Satoru
Yonemori, Kan
Shimizu, Toshio
Yamamoto, Noboru
Suzuki, Shigenobu
- License Information
-
More Information
Article History
Received: 31 May 2022
Accepted: 22 November 2022
First Online: 5 December 2022
Declarations
:
: This study was approved by the Institutional Review Board of NCCH (NCCH 2014–148). The study was conducted according to the principles of the Declaration of Helsinki.
: The informed consent was waived in accordance with the local regulation.
: Not applicable.
: ST has nothing to disclose. YK has nothing to disclose. YC has nothing to disclose. TM has nothing to disclose. TK has received grants from PACT Pharma, and personal fees from Chugai, and Sysmex. KS has received personal fees from Pfizer, Eisai, and AstraZeneca. TY has received grants from AMGEN, AstraZeneca, Takeda, Daiichi Sankyo, ONO Pharmaceutical Co., Ltd, MSD, Abbvie, Novartis, Chugai, Merck, Blueprint, and BMS, and personal fees from AstraZeneca, Takeda, Boehringer-Ingelheim, TAIHO, Chugai, Novartis, Lilly, MSD, ONO Pharmaceutical Co., Ltd, Roche, ArcherDX, Invitae, and BMS. SK has received grants from Chugai, Takeda, ASLAN, AstraZeneca, Eisai, Pfizer, Boehringer Ingelheim, Incyte, Lilly, Bristol Myers Squibb, MSD, and Astellas, and personal fees from Chugai, Takeda, Termo, Incyte, and Eisai. SI has received personal fees from Daiichi-Sankyo, Lilly, ONO Pharmaceutical Co., Ltd, Chugai, and Taiho. KY has received personal fees from Pfizer, Eisai, AstraZeneca, Lilly, Takeda, Chugai, Fuji Film Pharma, Novartis, and Genmab. TS has received grants from Novartis, Lilly, Daiichi-Sankyo, Abbvie, Bristol-Myers Squibb, Eisai, AstraZeneca, Pfizer, Loxo Oncology, Takeda, Incyte, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, Five Prime, and Astellas, and personal fees from Lilly, MSD, Chugai, Abbvie, Daiichi-Sankyo, Takeda, and Chordia Therapeutics. NY has received grants from Chugai, Taiho, Eisai, Lilly, Quintiles, Astellas, BMS, Novartis, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Bayer, ONO Pharmaceutical Co., Ltd, Takeda, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience Inc., Otsuka, Carna Biosciences, Genmab, and Shionogi, and personal fees from ONO Pharmaceutical Co., Ltd, Chugai, AstraZeneca, Pfizer, Lilly, BMS, Eisai, Otsuka, Takeda, Boehringer Ingelheim, Cimic, and Sysmex. SS has received personal fees from ONO Pharmaceutical Co., Ltd.
